Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome

NCT00346814 Phase 2/Phase 3 RECRUITING

Purpose:Retinopathy of prematurity (ROP) continues tobe a major cause of blindness in children. Although ablation of the retina with laser or cryotherapy reduces the incidence of blindness by suppressing the neovascular phase of ROP the visual outcomes after treatment are often poor. Vascular endothelial growth factor(VEGF) has an important role in the pathogenesis of ROP and inhibition of VEGF expression in the neovascular phase might prevent destructive neovascularization in ROP. The aim of this study is to determine the safety and efficacy of intravitreal bevacizumab in the treatment of retinopathy of prematurity

Details

Lead sponsor	Asociación para Evitar la Ceguera en México
Phase	Phase 2/Phase 3
Status	RECRUITING
Start date	2007-07
Completion	2024-11

Conditions

• Retinopathy of Prematurity

Interventions

• intravitreal injection

Primary outcomes

• Clinical appearance

Countries

Mexico